Johnson & Johnson Reports Worldwide Sales Increase of 1.3% in Fiscal 2022

 

Johnson & Johnson saw a worldwide increase of 1.3% in sales for fiscal year 2022, or $94.9 billion, the company reported on its official website.

 

Excluding acquisitions/divestitures on an operational basis, the worldwide increase was 6.2%.

 

Diluted earnings per share was $6.73 a decrease of 13.8%. Adjusted diluted earnings per share were $10.15, an increase of 3.6%. 

 

Worldwide Consumer Health sales were $15.0 billion, a 0.5% decrease, but saw an operational increase of 3.6%. Neutrogena, OB, Imodium, Tylenol, Sudafed and Motrin were primary drivers. 

 

“Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, CEO, J&J. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value.”